Celestoderm-V Ointment 0.1% 15g
Corticosteroids for dermatological use. Active corticosteroids (group iii). Betamethasone. ATX code D07A C01.
active substance: betamethasone;
1 g of ointment contains betamethasone 17-valerate is equivalent to 1 mg of betamethasone;
excipients: white soft paraffin, mineral oil.
Indications for use:
Local treatment of dermatitis, especially allergic dermatitis, toxic eczema, atopic dermatitis and psoriasis.
- hypersensitivity to active substances or to any of the excipients specified in the “Composition” section;
- acne vulgaris;
- generalized plaque psoriasis;
- perioral dermatitis;
- viral skin infections such as herpes simplex or chickenpox;
- skin lesions caused by a fungal or bacterial infection, in the absence of appropriate therapy for the infection.
- It is not recommended to use Celestoderm-B ointment under occlusive dressings (gypsum, etc.).
Method of administration and dosage:
Adult patients, incl. elderly patients Apply
1-3 times a day. The frequency of application is determined depending on the severity of the disease. In case of diseases of mild severity, application once a day is sufficient, while in severe forms of the disease, it is necessary to apply it 3 times a day.
Patients with renal or hepatic impairment
There are no data on the use of the drug Celestoderm-B in patients with renal or hepatic insufficiency.
Mode of application
For cutaneous use. Apply in a thin layer to the affected skin.
If irritation or signs of hypersensitivity occur when using the drug Celestoderm-B, treatment should be discontinued and appropriate therapy should be prescribed.
If antifungal / antibiotic therapy is concurrently prescribed due to the presence of an infection and a favorable response does not occur, the use of corticosteroids should be discontinued until signs of infection are eliminated.
Undesirable reactions, including suppression of adrenal function, can occur with the use of systemic corticosteroids. Adverse reactions can also occur with the use of topical corticosteroids, especially in children and infants.
Systemic absorption of topical corticosteroids increases with an increase in the size of the treated body surface. Therefore, certain precautions should be taken, especially with long-term treatment and when used in children and infants.
Due to the risk of simple glaucoma and subcapsular cataracts, Celestoderm-B is not intended for use in the eye area and for application to the eyelids.
Long-term use of potent topical corticosteroids can lead to atrophic changes, in particular on the face; other parts of the body are less sensitive. This should be borne in mind in the long-term treatment of conditions such as psoriasis, atopic dermatitis, and severe eczema. Application on the face should never last more than 5 days; no occlusive dressings should be used.
With the use of systemic and local corticosteroids, including intranasal, inhalation and ophthalmic use, visual impairment is possible. If symptoms such as blurred vision or other visual impairments occur, the patient should be examined by an ophthalmologist to assess possible causes of visual impairment, which may include cataracts, glaucoma, or rare conditions such as central serous chorioretinopathy, as reported after systemic and local action.
Since the ratio of surface area to body weight in children is greater than in adults, the degree of inhibition of the function of the hypothalamic-pituitary-adrenal system (HPAI) by local corticosteroids is higher in children than in adults.
In children treated with corticosteroids, there was inhibition of the function of the hypothalamic-pituitary-adrenal system (HPAI), Cushing’s syndrome, growth retardation, insufficient weight gain, and increased intra-abdominal pressure. Manifestations of suppression of the function of the adrenal cortex in children: low levels of cortisol in the blood plasma and lack of response to the test for stimulating the adrenal glands with the use of ACTH drugs (ACTH). Bulging fontanelle, headache, bilateral edema of the optic nerve head are manifestations of increased intracranial pressure.
Store in a dark place and out of reach of children at a temperature not exceeding 25 ºС
Produced in Belgium